New approach aims to shrink lung tumors before surgery
NCT ID NCT07450183
Summary
This study is testing whether giving an immunotherapy drug called cemiplimab before and after surgery can help people with early-stage lung cancer. It will enroll 33 patients whose cancer has a specific marker (PD-L1 ≥50%). The main goal is to see how much cancer is left in the tissue removed during surgery after patients receive three cycles of the drug beforehand.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henry Ford Health
Detroit, Michigan, 48202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.